Pharmacist Lead, Inpatient Oncology Clinical Support

The Pharmacist Lead, Inpatient Oncology Clinical Support, is a DFCI-employed pharmacist embedded at Beth Israel Deaconess Medical Center (BIDMC) or Mount Auburn Hospital (MAH). Reporting to the Pharmacy Manager of Orientation, Training, and Competency, this consultative role supports safe, consistent care for shared DFCI-oncology patients and ensures reliable bi-directional communication between inpatient care at BIDMC/MAH and ambulatory care at DFCI.

Located in Boston and the surrounding communities, Dana-Farber Cancer Institute is a leader in life changing breakthroughs in cancer research and patient care. We are united in our mission of conquering cancer, HIV/AIDS, and related diseases. We strive to create an inclusive, diverse, and equitable environment where we provide compassionate and comprehensive care to patients of all backgrounds, and design programs to promote public health particularly among high-risk and underserved populations.

We conduct groundbreaking research that advances treatment, we educate tomorrow's physician/researchers, and we work with amazing partners, including other Harvard Medical School-affiliated hospitals.

• Serves as a consistent “bridge” between BIDMC/MAH-inpatient pharmacists and DFCI inpatient-oncology providers, strengthening working relationships and streamlining communication
• Serves as an on-site oncology-pharmacy clinical resource for BIDMC/MAH teams for complex oncology-medication questions related to shared DFCI patients, providing real-time consultation support to reinforce safe oncology-medication practices
• Supports orientation, onboarding, and ongoing training of newly hired inpatient-oncology pharmacists at BIDMC or MAH, in collaboration with local pharmacy leadership, by providing DFCI-specific oncology-practice context, shared patient workflows, and key contacts/escalation pathways for DFCI-oncology patients
• Identifies recurring knowledge gaps or high-risk scenarios and coordinates targeted education with BIDMC/MAH-pharmacy leadership

• Establishes and maintains a reliable medication- and treatment-plan-handoff workflow for select high-risk DFCI patients discharged from BIDMC/MAH back to DFCI ambulatory care
• Communicates time-sensitive changes to DFCI ambulatory pharmacy teams, such as:
  • i. chemotherapy-plan changes, dose modifications, delays/holds, toxicity events impacting future therapy
  • ii. new or discontinued supportive care meds that affect ongoing outpatient management
  • iii. monitoring needs and follow-up medication plans tied to oncology therapy
• Anticipates downstream outpatient-access issues created by inpatient changes and alerts DFCI ambulatory pharmacy/clinic teams when action is needed (e.g., continuity of a specialty medication)

• Serves as the pharmacy liaison for the inpatient chemotherapy-approval/authorization process for shared DFCI-oncology patients
• Provides regimen-specific clarification support for shared DFCI patients
• Escalates patient-specific concerns to the appropriate DFCI-disease group/ambulatory team to align inpatient actions with the outpatient-treatment plan

• Serves as the DFCI-pharmacy liaison to BIDMC/MAH for inpatient medication-use policies with which DFCI intends to align
• Assists with policy-review cycles, and routes questions/updates through the appropriate governance channels at each institution (P&T, medication safety, etc.)

• Tracks and trends cross-site medication-related issues affecting…